International review of blood donation screening for anti-HBc and occult hepatitis B virus infection.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fu Michael X, Faddy Helen M, Candotti Daniel, Groves Jamel, Saa Paula, Styles Claire, Adesina Opeyemi, Carrillo Jose Perez, Seltsam Axel, Weber-Schehl Marijke, O'Brien Sheila F, Drews Steven J, Aidoo Nana Benyin, Pajares Ángel Luis, Perez Laura Navarro, Deng Xuelian, van de Laar Thijs, Laperche Syria, Lehtisalo Riikka, Yilmaz Soner, Tsoi Wai-Chiu, Juhl David, Niederhauser Christoph, Chenarsabz Nahid, O'Flaherty Niamh, Goto Naoko, Satake Masahiro, Renaud Christian, Lewin Antoine, Cloutier Marc, Sawadogo Salam, Reynolds Claire, Zhiburt Eugene, Muylaert An, Van Gaever Véronique, Garcia-Otalora Michel-Andres, Jarvis Lisa, Vermeulen Marion, Busch Michael, Blackmore Stuart, Jones Ann, Brailsford Su, Irving William L, Andersson Monique, Simmonds Peter, Harvala Heli, Virology subgroup of the ISBT WP‐TTID
Аннотация
MATERIALS AND METHODS: A questionnaire on HBV screening and follow-up strategies was distributed to members of the International Society of Blood Transfusion working party on transfusion-transmitted infectious diseases. Screening data from 2022 were assimilated and analyzed.
RESULTS: A total of 30 unique responses were received from 25 countries. Sixteen respondents screened all donations for anti-HBc, with 14 also screening all donations for HBV DNA. Anti-HBc prevalence was 0.42% in all blood donors and 1.19% in new donors in low-endemic countries; however, only 44% of respondents performed additional anti-HBc testing to exclude false reactivity. 0.68% of anti-HBc positive, HBsAg-negative donors had detectable HBV DNA. Ten respondents did universal HBV DNA screening without anti-HBc, whereas four respondents did not screen for either. Deferral strategies for anti-HBc positive donors were highly variable. One transfusion-transmission from an anti-HBc negative donor was reported.
DISCUSSION: Anti-HBc screening identifies donors with OBI but also results in the unnecessary deferral of a significant number of donors with resolved HBV infection and donors with false-reactive anti-HBc results. Whilst confirmation of anti-HBc results could be improved to reduce donor deferral, transmission risks associated with anti-HBc negative OBI donors must be considered. In high-endemic areas, highly sensitive HBV DNA testing is required to identify infectious donors.